About This Journal

Cardiac and Cardiovascular Research (CCR) is an international open access journal. It provides various academic researches in this field from different aspects. All the manuscprits received will undergo a rigorous double blind peer-reviewed process. Cardiac and cardiovascular deseases refer to the deseases involve the heart and blood vessels. Cardiac and cardiovascular deseases are the leading cause of death worldwide except Africa. This journal enhances the understanding of the treatment of cardiac and cardiovascular desease. It will also help with the treatment of cardiac and cardiovascular deseases. This journal makes research outputs publicly available and allows for different types of articles including original research articles, book reviews, editorials, commentaries, case report, etc.

Focus and Scope

Cardiac and cardiovascular research (CCR) is an international open access journal. It provides various academic researches in this field from different aspects. All the manuscprits received will undergo a rigorous double blind peer-reviewed process. Cardiac and cardiovascular deseases refer to the deseases involve the heart and blood vessels. Cardiac and cardiovascular deseases are the leading cause of death worldwide except Africa. This journal enhances the understanding of the treatment of cardiac and cardiovascular desease. It will also help with the treatment of cardiac and cardiovascular deseases. This journal makes research outputs publicly available and allows for different types of articles including original research articles, book reviews, editorials, commentaries, case report, etc.

 

The journal will specifically address the following topics but not limited to:

  • Heart deseases
  • Cardiovascular medicine
  • Disorder of heart
  • Cardiology
  • Coronary artery desease
  • Diagnosis treatment of heart desease

For Authors

  • APASCI upholds the spirit of strict adherence to high ethical standards. This is consistent with APASCI’s mission of publishing high-quality articles and promoting open scientific exchanges globally. APASCI follows the Ethical Oversight Guidelines of the Committee on Publication Ethics (COPE) in overseeing the publication process, as well as the activities of APASCI journals, editors, and reviewers.

    APASCI and all the editors adhere to the following guidelines:

    1. Core Practices and Best Practice Guidelines of the Committee on Publication Ethics (COPE);

    2. Principles of Transparency and Best Practice in Scholarly Publishing developed by the Committee on Publication Ethics (COPE)Directory of Open Access Journals (DOAJ), Open Access Scholarly Publishers Association (OASPA), and World Association of Medical Editors (WAME).

    3. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals from the International Committee of Medical Journals Editors (ICMJE).

    APASCI is committed to protecting the privacy of its contributors and promises not to disclose personal information to third parties without permission, unless for necessary purposes of the publishing process or required by law.

    APASCI takes allegations of misconduct (refer to the Misconduct Policy for more details) seriously and will launch an immediate investigation by a group of investigation members. Decisions will be made by the investigation group based on clear evidence, and the authors will be informed. If there is any appeal against the decision, it must be made to the publisher within 14 days of the decision date, or else actions will be taken after 14 days. The decision on the appeal is final.

    Any complaints and appeals against APASCI journals and editors can be directed to the publisher at editorial_office@apacsci.com, and APASCI follows COPE guidelines in handling all complaints and appeals.

    Research Involving Human Subjects

    Authors who carry out research involving humans must declare that their studies followed the WMA Declaration of Helsinki. They must obtain approval from the concerned research ethics committee before carrying out the research and accept the monitoring by the committee. During the submission stage, authors are required to attach a statement containing the name of the ethics committee, the approval code, etc.

    Informed consent to participate in the research must be obtained from all human subjects or their guardians. A statement on the consent to participate should also be included during submission. If there is no need for informed consent, authors must provide the name of the ethics committee and the reason for the absence of the need for informed consent.

    Human subjects’ right to privacy right is inviolable. Authors should not disclose any identifying information, including but not limited to names, initials, contacts, and medical record numbers, unless the absence of such information may influence the interpretation of the research. In addition, written informed consent for publication from the participants should be obtained. If participants are vulnerable, informed consent should be given by their guardians. Authors must inform the participants if pictures of their bodies (e.g., faces) have to be included in the manuscript and receive consent for publication. In the case of deceased human subjects, their next of kin or legal representative should be asked for consent.

    Research Involving Animal Subjects

    All studies involving animals should be approved by an ethics committee before the research is conducted. If ethical approval is not required by national laws, exemption from the ethics committee, the name of the ethics committee, and the reason should be provided by the authors during submission.

    The following guidelines can be helpful for authors in upholding high ethical standards and avoiding submission rejection

    APASCI applies The ARRIVE Essential 10: Compliance Questionnaire for evaluating comparative experiments in living animals. Authors can also use it as a checklist.

  • Based on the guidelines of the International Committee of Medical Journal Editors (ICMJE), authorship should be limited to those who meet the following four criteria:

    1. Contributed substantially to the conception or design of the manuscript or the acquisition, analysis, or interpretation of data for the manuscript; AND
    2. Drafted the manuscript or reviewed it critically for significant intellectual content; AND
    3. Have final approval of the version to be published; AND
    4. Agreed to be responsible for the manuscript in ensuring that problems relating to the accuracy or completeness of any part of the manuscript are appropriately investigated and resolved.

    Individuals who do not meet the above four criteria should not be listed as authors but should be acknowledged. Authors should disclose whether artificial intelligence (AI)-assisted technologies were used in the preparation of their manuscripts and how they used them. Authors should also report the use of AI for writing assistance in the Acknowledgment section. AI tools should not be used in sections that rely on human intellectual analysis, such as data interpretation and conclusion summarization.

    Changes to Authorship

    Authorship changes (addition, deletion, or rearrangement of author names) should be made before the acceptance of the manuscript. Confirmation from all authors (including existing authors and author(s) to be added and/or removed) should be provided to the editorial office of the journal, together with the reason for such changes. Changes can be made after the approval of the journal.

  • Authors are required to declare any potential conflicts of interest (financial or non-financial). Any agreements with study sponsors (for-profit or non-profit), such as those that interfere with the authors’ access to the study’s data or with the authors’ ability to analyze or interpret the data and to publish manuscripts independently according to their own decision, should be avoided by authors at all costs.

    APASCI also requires reviewers and editors to declare any (potential) non-financial conflicts of interest and declare any unpaid roles or relations that may influence the decision on the manuscript’s publication. These include, but are not limited to, unpaid roles in a governmental or non-governmental organization, unpaid roles in an advocacy or lobbying organization, and unpaid advisory positions in a commercial organization.

    In addition, reviewers and editors must disclose any association that poses a conflict of interest in connection with the manuscript. Examples are personal or work-related relationships with one of the authors or the reviewer is on the authors’ avoidance list.

  • Following COPE guidelines, APASCI will not accept any misconduct behaviors that may mislead researchers.

    Plagiarism

    Plagiarism is not acceptable. Using the content from one’s own previously published articles without proper citation is also considered plagiarism. APASCI adopts Crossref Similarity Check (powered by iThenticate) for checking the originality of submissions. Manuscripts with a high similarity index may be rejected.

    Fabrication and falsification

    Fabrication and falsification of data or images will mislead researchers. APASCI strongly opposes such practices and will reject suspicious submissions.

    Duplicate submission

    Duplicate submission of a manuscript that has been published or submitted to other journals at the same time will not be considered.

  • The language of all manuscripts must be English (either British or American) and non-English words should be used sparingly. Poor English may lead to article rejection. Authors are encouraged to seek language polishing by a native English speaker or a professional editing service.
  • Correction

    Authors are responsible for approving the final version of their manuscript and they should avoid any errors prior to publishing. In the case of errors that occur in a published article and have no influence on research results, APASCI will issue a correction/erratum.

    Authors, readers, and editors are encouraged to report any errors found in published papers. Please contact the editorial office of the particular journal.

    Retraction

    Based on COPE guidelines, the following conditions can lead to the retraction of a published article:

    • Unreliable findings
    • Plagiarism
    • Published elsewhere without proper attribution to previous sources, disclosure to the editor, permission to republish, or justification
    • Containing material or data without the authorization for use
    • Infringement of copyright, violation of privacy, or other legal issues
    • Unethical research
    • Dubious peer review processes
    • Failing to disclose a major competing interest

    If any of the above misconduct proved to be true, a retraction notice will be issued with the reason, while the PDF of the retracted article will be watermarked with “Retracted”. The journal editors will inform the authors of the retraction.

    Paid Article Processing Charges will not be refunded to the authors if retraction occurs.

    Withdrawal

    Although not encouraged, authors can initiate the withdrawal of their submission before and during the peer review process by providing the reason. However, authors should note that a penalty fee of US$200 will be imposed for the withdrawal of a submission undergoing the peer review process due to the spent efforts on the evaluation of the manuscript by the editors and reviewers. Upon the approval of submission withdrawal, the submission will be removed from the journal’s operation system, and the authors be informed.

    Accepted articles and articles in press may also be withdrawn due to infringements of professional ethical codes (similar reasons to those for retraction).

  • APASCI allows authors to post preprints of the manuscript of their original research articles (limited to only this type of article) on community preprint servers, such as arXiv, bioRxiv, and PeerJ Preprint, prior to or simultaneous with their manuscript submission to APASCI journals. Authors retain the copyright of the manuscript posted on a preprint server.

    Authors should inform the editors of the preprint version of their submitted manuscript in a cover letter, as well as provide any associated accession numbers or DOIs. Revised versions per the result of the peer review process and accepted versions for publication should not be posted on a preprint server.

    Upon publication of the article, APASCI encourages authors to link the article in the preprint server to the journal site, so as to guide readers to access and refer to the final version of the article.

  • Authors should read the “Author Guidelines” before making a submission, and make sure that the manuscripts were written in accordance to the style and specifications of the journal’s policy.

    All manuscripts submitted to Cardiac and Cardiovascular Research are subject to rigorous peer review. Prior to peer review process, the manuscripts will be screened for acceptable English language, novelty and relevance to the Focus and Scope of the journal.

    Any manuscripts submitted to Cardiac and Cardiovascular Research will be treated as confidential materials. The manuscripts will not be disclosed to anyone except individuals such as editorial staff, reviewers and editors who participate in the initial screening, review, processing and preparation of the manuscript for publication (if accepted).

    A manuscript would not be accepted if it has been published or is currently under consideration for publication in any other journals. The authors are required to notify the editorial team if the findings and data in their submissions have been presented in conferences.

     

     

  • The opinions, statements, methods, results, and data in APASCI’s published articles are those of the authors and do not reflect the opinions of APASCI and its editors. APASCI disclaims responsibility for any injury to people or property resulting from any ideas, methods, or products referred to in the articles or advertisements.

  • Authors contributing to APASCI journals retain the copyright.

    All articles published by Cardiac and Cardiovascular Research are licensed under the Creative Commons International Licenses. Without any explicit request from the corresponding author during the submission stage, a paper will be published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) by default. Authors who would like to publish their work under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), should express their request during the submission stage. Please include the statement below in the "Comments for the Editor column" on the submission page:

    The contributors or authors for this submission entitled “[MANUSCRIPT TITLE]”, i.e. [NAMES of ALL AUTHORS], have given their consents to alter the Creative Commons License to *CC BY-NC 4.0* under which this submission will be published in Cardiac and Cardiovascular Research.

     

     

     

    1. APASCI reserves the right to accept or refuse advertising.
    2. Advertisements must comply with relevant rules and laws in the country where they will appear.
    3. Advertisements should be clearly legible and advertisers identifiable.
    4. Advertisements should never influence the content of each journal and editorial decisions.
    5. APASCI disclaims responsibility for any damages resulting from advertisements in its journals.

    For more inquiries, please send email to editorial-ccr@apacsci.com.

    • All the articles published online will be archived by Portico for long-term digital preservation.
    • Authors are encouraged to self-archive the final version of their published articles into institutional repositories (such as those listed in the Directory of Open Access Repositories).
    • Authors are also encouraged to use the final PDF version published on the website of Cardiac and Cardiovascular Research.
     
    Cardiac and Cardiovascular Research (CCR) has be indexed by several world-class abstracting/indexing databases:
    •    Google Scholar
    •    Scilit
     
    We aims to be included in the first-class academic databases in the world, such as WoS, Scopus, Inspec, and EI
  • 1. What is a Special Issue?

    A Special Issue Program has been launched by Asia Pacific Academy of Science Pte. Ltd. A Special Issue is a collection of research hotspots or topics in a specific field. Guest Editors who are experts in this discipline, have the responsibility to drive the special issue program. Manuscripts accepted will both be ordered/archived in a regular volume/issue and a special issue.

    Benefits of Special Issue

    • Being more quickly discovered and cited.
    • Promoting academic exchanges in this field.
    • Avoiding repetition of topics.
    • Disseminating the latest achievements.
    • Broadening the visibility and maximizing the impact of a certain field so that more experts could focus on the topic.

    Benefits of being Guest Editors

    • Expanding the popularity.
    • Initiating the communication and establishing co-operatives ties faster.
    • Learning the latest research.
    • Publishing one article without any APCs as the privilege.

    2. How to drive a Special Issue?

    There are two ways to obtain a special issue proposal.

    • Guest Editors will be invited by assistant editors to submit a professional proposal.
    • Authors and readers are welcomed to submit proposals via emailing to editorial-ccr@apacsci.com, and EiC will evaluate them for the viability and suitability for this journal.

    Preparation for a proposal

    A great topic is the crucial element for success. Each candidate topic will be selected by EiC for considering whether it is consistent with the scope of this journal. Hot topics are usually considered to be more attractive.

    A proposal should include necessary information:

    • List of Guest Editors
    • Types of manuscript
    • Main topics
    • Submission deadline
    • Keywords

    3. Special Issue Ethics

    APASCI abides to the Code of Conduct of the Committee on Publication Ethics (COPE) and Best Practice Guidelines in all the editorial process. Each new submission must follow the journal’s Editorial Policies, and any potential unethical manuscripts will not be passed to the nest stage. APASCI promises to protect the confidentiality of all submissions unless the publishing needs. All the editors and reviewers must strictly abide by the Conflict of Interest of the journal, and they are asked to inform the Editorial Office if any potential conflicts of interest exist, and then, the Editorial Office may consider to change the editor or reviewer. As authors, they have the right to provide a list of avoided experts. Please appeal to editorial-ccr@apacsci.com for any requests related to manuscript promotion.

    4. Workflow of a Special Issue

    Manuscripts should be submitted to Open Journal Systems (OJS) and go through a double-blinded peer-reviewed process (refer to Peer Review Policy).

  • Researchers using an Artificial Intelligence Generated Content (AIGC)  tool/service to directly generate the manuscript text must provide clear disclosures and statements, otherwise it will be considered academic misconduct. The journal allows the use of an AIGC tool/service for text embellishment and automatic sorting of references, but does not recommend the use of the AIGC tool/service in the thinking and concluding sessions of human involvement such as data analysis and interpretation, opinion hypothesis and conclusions, and the AIGC tool/service cannot fulfill the role of a textual author. If any part of the manuscript was written using an AIGC tool/service, it must be described openly, transparently, and in detail in the Methods or Acknowledgments section, for example:

    "In the preparation of this work, the authors used the [name of the specific AIGC tool/service] to [purpose of use: e.g., literature research/text embellishment, etc.]. After using this tool/service, the authors reviewed and edited the content as needed, and take full responsibility for the content of the publication."

  • Author Guidelines

    Before your submission, please check that your manuscript has been prepared in accordance to the step-by-step instructions for submitting a manuscript to our online submission system.

    Manuscript Format

    The manuscript should be in MS Word or LaTeX format. The language of all manuscripts must be English (either British or American) and non-English words should be used sparingly. Poor English may lead to article rejection. Authors are encouraged to seek language polishing by a native English speaker or a professional editing service.

    Article Types

    Please refer to the Section Policy for choosing an appropriate type.

    Cover Letter

    Authors should attach a cover letter together with the article text. A cover letter should contain a brief explanation of the significance of their work and the intention of doing the work. If the work involves the human and animal research, authors should provide the Informed Consent Statement or Ethical Approval ID attached with cover letter. The cover letter is confidential and will be read only by the editors. It will not be seen by the reviewers.

    Article Title

    Titles should be no more than 50 words, with significant and attractive information for readers. Titles should not include uncommon jargons, abbreviations, and punctuation.

    List of Authors

    The list of authors should be arranged based on the level of their contribution, with the major contributor listed first. Corresponding authors should be marked with an asterisk (*). Affiliation information should be provided with the following elements: department, institution, city, postal code (if available), and country. The email address of at least one corresponding author must be provided. All authors must approve the final version of the manuscript and agree with the submission. For more information about authorship, please refer to our Authorship Policy.

    Abstract and Keywords

    Depending on the article type, an abstract should be provided, which gives a concise summary of the article. It is usually a single paragraph of about 200–250 words maximum. Between 5–8 keywords should be included. Words and phrases in article titles should be avoided as keywords.

    Text

    The text of manuscripts should be in MS Word or LaTeX format. Original research articles should include the Introduction, Materials and Methods, Results, Discussion, and Conclusion (optional) sections.

    Section Headings

    Headings are used to indicate the hierarchy of the sections of the text. No more than three levels of headings should be employed. The first level of heading should be numbered as 1., 2., 3., 4. in boldface. Likewise, the second and third levels of headings should also be in boldface, for example, 1.1., 1.2., 1.1.1., 1.1.2.

    Introduction

    The introduction should provide a background that gives the broad readership an overall outlook on the field and the research performed. It pinpoints a problem and states the significance of the study. The introduction can conclude with a brief statement on the aim of the work and a comment about whether that aim was achieved.

    Materials and Methods

    This section provides the general experimental design and methodologies used. The aim is to provide enough details for other investigators to fully replicate the experiments. It is also to facilitate a better understanding of the results obtained.

    Results

    This section can be divided into subheadings. This section focuses on the results of the experiments performed.

    Discussion

    This section should provide the significance of the results and identify the impact of the research in a broader context. It should not be redundant or similar to the content of the Results section.

    Conclusion (Optional)

    The conclusion section can only be used for interpretation, and not be used to summarize information already presented in the text or abstract.

    Figures and Tables

    Figures (photographs, images, graphs, charts, and schematic diagrams) and tables should be referred to within the main text and numbered consecutively as Figure 1Figure 2Table 1Table 2, etc. They should be placed as close as possible to where they are first cited and center-aligned. Both figure captions and table captions should be center-aligned, with figure captions set underneath the figures and table captions above the tables. When captions are longer than one line, they should be left-aligned.

    Figures can contain multiple panels. They should be numbered by Latin letters with parentheses, e.g., (a)(b)(c), or (A)(B)(C), placed below the image or within the image.

    Tables should be in MS Word/Excel table format. Tables containing too much information can be provided as supplementary material.

    In the main text, all figures and tables should be cited, e.g., “Table 1 indicates…”, “Figures 1 and shows…”, and “Figure 1a,b shows…”.

    Lists and Equations

    Both bulleted lists and numbered lists are acceptable (refer to the template). Equations should be center-aligned and equation numbers should be right-aligned. If cited in the text, equations should be labeled with numbers in parentheses, e.g., Equation (1).

    In-Text Citations

    All bibliographical references that make an important contribution to the article should be numbered according to the appearance order. When cited in the text, the number should be placed in square brackets, for example:

    • Negotiation research spans many disciplines [3,4].
    • This effect has been widely studied [1–5,7].

    Appendix (Optional)

    An appendix provides information supplementary to an article and is included at the end of the article after the References section and it should start on a new page. For one appendix, it is designated as “Appendix”; for more than one appendix, they are designated “Appendix A”, “Appendix B”, etc.

    An appendix should be cited in the main text. Tables, figures, and equations should be started with the prefix A (i.e., Figure A1, Figure A2, Table A1, etc.).

    Back Matter

    The sequence of back matter elements in an article is listed below. There is no numeral label for back matter headings. Some of these elements are optional.

    Supplementary materials (Optional)

    The Supplementary Materials section provides a short description of the supplementary materials. One or more individual supplementary files are allowed and should be submitted in Step 4 during submission. These materials are relevant to the manuscript but remain non-essential to readers’ understanding of the article’s main content. Please ensure the names of such files contain “suppl. info”. Videos may be included in this section.

    Author contributions

    For original research articles, this section is required, except when there is only one author for the article. The contribution of each co‐author should be reported in this section.

    The following statements should be used “Conceptualization, XX and YY; methodology, XX; software, XX; validation, XX, YY and ZZ; formal analysis, XX; investigation, XX; resources, XX; data curation, XX; writing—original draft preparation, XX; writing—review and editing, XX; visualization, XX; supervision, XX; project administration, XX; funding acquisition, YY. All authors have read and agreed to the published version of the manuscript.”

    Funding (Optional)

    Authors can acknowledge financial support in this section, which is NOT mandatory. If authors provide a funding statement, it should be in the same style as the template.

    For example:

    “This research was funded by [name of funder] grant number [xxx]” and “The APC was funded by [XXX]”. Please check carefully that the details given are accurate and that the standard spelling of the funding agency’s name in https://search.crossref.org/funding is used, as any errors may affect the authors’ future funding.

    Acknowledgments (Optional)

    Authors can acknowledge any support and contribution that cannot be included in the Author Contributions and Funding sections. This section is NOT mandatory.

    Conflict of interest

    According to our Conflict of Interest Policyall authors are required to declare all activities that have the potential to be deemed as a source of competing interest in relation to their submitted manuscript. Examples of such activities include personal or work-related relationships and events. Authors who have nothing to declare should add “No conflict of interest was reported by all authors” or “The authors declare no conflict of interest” in this section.

    References

    This section is compulsory and should be placed at the end of the manuscript. Footnotes or endnotes should not replace a reference list. The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications should be excluded from this section.

    The format of author names should be “Last-Name Initial”, e.g., David Smith should be written as Smith D.

    Journal

    Journals in English:

    • Author AA, Author BB, Author CC, et al. Title of the article. Journal Name. Year, Volume(Issue) (if available): Firstpage–Lastpage. doi (if available)

    Journals in languages other than English:

    • Author AA, Author BB, Author CC, et al. English title of the article (original language). Journal Name. Year, Volume(Issue) (if available): Firstpage–Lastpage. doi (if available)

    Book

    A book without editors:

    • Author AA, Author BB. Chapter (optional). Title of the Book, Edition (if available). Publisher; Year. pp. Page range (optional).

    A book with editors:

    • Author AA, Author BB. Title of the contribution. In: Editor CC, Editor DD (editors). Title of the Book, Edition (if available). Publisher; Year. Volume (optional), pp. Page range (optional).

    For a translated book, the translators’ names should be placed after the editors’ names: “Translator AA (translator)” or “Translator AA, Translator BB (translators)”.

    If the editors and translators are the same, the format should be as follows:

    • Author AA, Author BB. Title of the contribution. In: Editor CC, Editor DD (editors and translators). Title of the Book, Edition (if available). Publisher; Year. Volume (optional), pp. Page range (optional).

    Conference

    Full citations of published abstracts (proceedings):

    In most cases, proceedings will be simply called “Proceedings of the Name of the Conference (full name)” without a book title. In this case, please only add the conference name in the proceedings’ title and keep that in regular font (i.e., do not italicize):

    • Author AA, Author BB, Author CC, et al. Title of presentation. In: Proceedings of the Name of the Conference; Date of Conference (Day Month Year) (if available); Location of Conference (City, Country) (if available). Abstract Number (optional), Pagination (optional).

    If the proceedings are published as a book with a separate title (i.e., not “Proceedings of the Name of the Conference (full name)” as the title), the book title should be included:

    • Author AA, Author BB, Author CC. Title of presentation. In: Editor DD, Editor EE (editors) (if available). Title of Collected Work, Proceedings of the Name of the Conference; Date of Conference (Day Month Year) (if available); Location of Conference (City, Country) (if available). Publisher; Year. Abstract Number (optional), Pagination (optional).

    Oral presentations without published material:

    • Author AA, Author BB, Author CC. Title of presentation (if any). Presented at the Name of Conference; Date of Conference (Day Month Year) (if available); Location of Conference (City, Country) (if available); Paper number (if available).

    Thesis/Dissertation

    • Author AA. Title of Thesis [Level of thesis]. Degree‐Granting University; Year.

    The level of thesis can be called “XX thesis” or “XX dissertation”. Thesis types include but are not limited to the following:

    • PhD thesis
    • Master’s thesis
    • Bachelor’s thesis
    • Licentiate thesis
    • Diploma thesis

    Newspaper

    • Author AA, Author BB, Author CC, et al. Title of article. Title of Periodical, Complete Date, Pagination (if available).

    Patent

    • Patent Owner AA, Patent Owner BB, Patent Owner CC. Title of Patent. Patent Number, Date (Day Month Year, the Application granted date).

    Unpublished work

    • Author AA, Author BB. Title of unpublished work. Journal Title. Year (if available); Phrase Indicating Stage of Publication (submitted, in press, etc.).

    Online resources

    • Author (if available). Title of content (if available). Available online: http://URL (accessed on Day Month Year).

    For a homepage, the access date is not required.

  • Authors contributing to this journal agree to publish their articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear. With this license, authors hold the copyright without restrictions and are allowed to retain publishing rights without restrictions as long as this journal is the original publisher of the articles.

  • Asia Pacific Academy of Science Pte. Ltd. (APASCI) is devoted to protecting authors’ privacy. With APASCI’s privacy policy, authors can rest assured of their privacy in collaborating with APASCI.

    1. Personal information

    APASCI collects personal information when individuals register on a journal site (e.g., as an author), when the editorial office helps them register (e.g., as a reviewer), or when they communicate with APASCI or subscribe to APASCI notifications. Information, including name, title, affiliation, country, and e-mail address, will be treated as private and only used for activities involving manuscript processing. APASCI will not disclose any personal information to third parties. This policy also applies to the information of the co-authors of submissions.

    APASCI collects some other information when individuals visit the APASCI website, such as log data, device information, IP address, time of visit, and visitor interaction. These data are used for optimizing APASCI’s service, gathering statistics on articles, and promoting the APASCI website.

    Registered individuals can access their accounts or make corrections to their personal information. They also have the right to request APASCI to delete their information.

    2. Third-party links

    APASCI is not responsible for any consequences caused when visitors to the APASCI website are linked or directed to a third-party website.

    3. Contact APASCI

    For any questions regarding APASCI’s privacy policy, please send an email to editorial_office@apacsci.com.

APC Payment

Payments for APC of this journal can be made through our online PayPal payment gateway. Enter the article no. into the below textbox and select "Pay Now" to proceed with payment.

*Article No.

*Article No. is mandatory for payment and it can be found on the acceptance letter issued by the Editorial Office. Payment without indicating Article No. will result in processing problem and delay in article processing. Please note that payments will be processed in USD. You can make payment through Masters, Visa or UnionPay card.



Latest Articles
Open Access
Article
Carlos Guamán, William Acosta, Carla Alvarez4, Benhard Hasbum
Cardiac. Cardiovasc. Res. 2023 , 4(2); doi: 10.54517/ccr.v4i2.1918
Article lD: 1918
Abstract

Diabetes mellitus is one of the main causes of morbidity and mortality worldwide. This group of patients generally represents a population at high or very high cardiovascular risk, which is why early risk stratification is performed, seeking to focus objectively on the pharmacological and nonpharmacological approach with an intensive strategy. Cardiovascular disease represents the main cause of mortality, but in recent years there have been advances in therapeutics that have been shown to reduce major cardiovascular events. This article reviews the interaction between diabetes, cardiovascular disease and its treatment.

read more
Open Access
Article
Jorge Trainini, Mario Beraudo, Mario Wernicke, Alejandro Trainini, Diego Haber Lowenstein, María Elena Bastarrica, Darío Carlos Martino, Jorge Lowenstein
Cardiac. Cardiovasc. Res. 2023 , 4(2); doi: 10.54517/ccr.v4i2.1919
Article lD: 1919
Abstract

Objective: The cardiac muscle cannot be anatomically free in the thorax and without a support to fulfill its hemodynamic function. Therefore, the possibility of the existence of a support point acting as a lever was analyzed.

Material and methods: We used: 1) cardiac dissection in ten young bovine hearts [800-1000 g]; 2) cardiac dissection in eight human hearts: one embryo of 23 weeks gestation; one 10 year old, 250 g; and six adults, mean weight 300 g. The myocardial band was unwound completely. The myocardial band was uncoiled in its entirety. The extracted pieces were analyzed for anatomy and histology. The investigation was completed with simple radiographic imaging studies, magnetic resonance imaging and computed tomography. Results: In anatomical investigations we have found in all human and bovine hearts studied a nucleus underlying the right trigone of bone-chondroid-tendinous histological structure. Microscopic analysis revealed in bovine hearts a trabecular osteochondral matrix [fulcrum]. In all human hearts the fulcrum was found to be formed by chondroid tissue. In this structure, not described by other authors, the origin and end of the myocardial fibers have muscular insertion. Imaging techniques confirmed its existence. Conclusions: The cardiac fulcrum found in the anatomical investigation of human and bovine hearts would clarify about the necessary fulcrum of the myocardial muscle to complete its twisting movements.

read more
Open Access
Article
Triana-Alcívar Héctor, Ureta-Pilligua Jordy, Mera-Flores Ronny Richard, Bermúdez Cevallos Leonardo, Rivadeneira Mendoza Yokasta
Cardiac. Cardiovasc. Res. 2023 , 4(2); doi: 10.54517/ccr.v4i2.1920
Article lD: 1920
Abstract

Historically, the heart has been considered a vital organ due to its function as an impeller and aspirating blood pump, allowing the fi siological perfusion to every corner of the human body. However, behind this pump role lies a little-discussed function, that is, the endocrine-metabolic role of the heart, as a hormone synthesizing organ and, because of its pump function, a distributor of hormones foreign to it. Understanding the incidence of peptides synthesized in the heart offers a new perspective on the relevance of the heart in homeostasis and how cardiovascular disease can alter metabolism. The present work aims to review the most current information on the role of natriuretic peptides produced in the heart and their endocrine-metabolic function. These are atrial, brain and C-type natriuretic peptides. It is concluded that the conception of the heart as an organ of endocrine-metabolic regulation, whose hormones are essential for the homeostasis of the organism, is fundamental for the medicine of this century and for future advances in new therapeutic strategies to improve the quality of life of patients.

read more
Open Access
Article
Li Yan, Zhiru Ge
Cardiac. Cardiovasc. Res. 2023 , 4(2); doi: 10.54517/ccr.v4i2.1921
Article lD: 1921
Abstract

Long non coding RNA (lncrna) is a highly conserved non coding RNA (ncRNA) with a length of more than 200 nucleotides. Studies have found that lncrna is closely related to transcriptional regulation, post transcriptional regulation and apparent regulation, and thus participates in the regulation of cardiovascular physiology and pathophysiology. This article summarizes the current biological characteristics of circulating lncrna, the value of lncrna as a potential biomarker of cardiovascular diseases and the future prospects of therapeutic methods.

read more
Open Access
Article
Abudixiaokuer Mureti, Yan Feng
Cardiac. Cardiovasc. Res. 2023 , 4(2); doi: 10.54517/ccr.v4i2.1922
Article lD: 1922
Abstract

Objective: To investigate the effect of obstructive sleep apnea hypopnea syndrome (OSAHS) on cardiac autonomic nervous homeostasis. Methods the patients with OSAHS diagnosed in our hospital were the observation group, and the non OSAHS patients in the same period were the control group. The differences of baseline data, sleep monitoring, time domain analysis index of heart rate variability, peripheral blood methoxyepinephrine (MN) and methoxynorepinephrine (NMN) between the two groups were analyzed. The observation group was divided into light, medium and heavy groups according to apnea index (AHI), and the correlation analysis between age, AHI, lsao2, time domain index and blood catecholamine metabolites was carried out. Results: Ahi was negatively correlated with SDNN and PNN50% (P <0.01) and positively correlated with NMN (p<0.05); lsao2 was positively correlated with SDNN and PNN50% (P <0.05), and negatively correlated with vanillic acid 2 (p<0.05). Conclusion patients with OSAHS have obvious disturbance of cardiac sympathetic and vagus nerve balance at night.

read more
Open Access
Article
Ramaiyan Velmurugan, J. Dhanush
Cardiac. Cardiovasc. Res. 2023 , 4(2); doi: 10.54517/ccr.v4i2.2114
Article lD: 2114
Abstract

Objectives: Cocaine is regularly utilized topically to give the vasoconstriction to nasal medical procedure; However, it is said to create intraoperative cardiovascular unfriendly impacts. Methylphenidate was considered in the place of cocaine as a substitute to look at the vasoconstriction in nasal medical procedure. Methods: Outcome of the study will be examining the vasoconstriction based on a 5-point scale (1 = unacceptable, 5 = excellent), followed by the administration of either 20–30 mg per day methylphenidate or 4% cocaine randomly to the adult patients subjected to nasal septoplasty. Results: Methylphenidate and cocaine were administered with 38 and 28 patients respectively. The quality of vasoconstriction was noticed to be good in both the groups with the median rating of 4.0 and a P value of 0.85. With both the gatherings, the median blood loss was 46 and 58 ml with a p estimation of 0.48. A non-mediocrity delta of 1 point with a p estimation of 0.009 and non-inadequacy delta of 24 ml with a p esteem 0.026 concerning vasoconstriction and blood loss individually is seen which demonstrates methylphenidate is comparable to cocaine. Non importance is noted with the recurrence of ventricular ectopy, ST section changes after nasal packing with the gatherings. Conclusions: With the results obtained, methylphenidate can be very well replaced for cocaine for vasoconstriction in septoplasty. As there are lot many underlying chances for cocaine abuse and administrative issues related to its handling, methylphenidate may serve as a substitute.

read more